Congrats f_老虎社区_美港股上老虎 - 老虎社区

Congrats for the good news!

恒瑞医药(600276.SH)：恒曲获批开展治疗恶性肿瘤化疗所致血小板减少症Ⅲ期临床试验

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":697134127,"tweetId":"697134127","gmtCreate":1642348302998,"gmtModify":1642348303297,"author":{"id":3579743164156658,"idStr":"3579743164156658","authorId":3579743164156658,"authorIdStr":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":23,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Congrats for the good news!</p></body></html>","htmlText":"<html><head></head><body><p>Congrats for the good news!</p></body></html>","text":"Congrats for the good news!","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/697134127","repostId":2202204789,"repostType":2,"repost":{"id":"2202204789","kind":"news","pubTimestamp":1641890451,"share":"https://www.laohu8.com/m/news/2202204789?lang=&edition=full","pubTime":"2022-01-11 16:40","market":"sh","language":"zh","title":"恒瑞医药(600276.SH)：恒曲获批开展治疗恶性肿瘤化疗所致血小板减少症Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2202204789","media":"智通财经","summary":"智通财经APP讯，恒瑞医药(600276.SH)公告，近日，公司收到美国食品药品监督管理局(“美国FDA”)关于同意海曲泊帕乙醇胺片进行临床试验的函，将于近期开展Ⅲ期临床试验。试验通俗题目：海曲泊帕治疗恶性肿瘤化疗所致血小板减少症的Ⅲ期临床研究试验。据悉，海曲泊帕乙醇胺片(商品名：恒曲)于2021年6月获得国家药品监督管理局批准用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者的治疗，以及用于对免疫抑制治疗疗效不佳的重型再生障碍性贫血成人患者的治疗。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600276\">恒瑞医药</a>(600276.SH)公告，近日，公司收到美国食品药品监督管理局(“美国FDA”)关于同意海曲泊帕乙醇胺片进行临床试验的函，将于近期开展Ⅲ期临床试验。试验通俗题目：海曲泊帕治疗恶性肿瘤化疗所致血小板减少症的Ⅲ期临床研究试验。</p><p>据悉，海曲泊帕乙醇胺片(商品名：恒曲)于2021年6月获得国家药品监督管理局批准用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者的治疗，以及用于对免疫抑制治疗疗效不佳的重型再生障碍性贫血成人患者的治疗。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药(600276.SH)：恒曲获批开展治疗恶性肿瘤化疗所致血小板减少症Ⅲ期临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药(600276.SH)：恒曲获批开展治疗恶性肿瘤化疗所致血小板减少症Ⅲ期临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-11 16:40 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/638846.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，恒瑞医药(600276.SH)公告，近日，公司收到美国食品药品监督管理局(“美国FDA”)关于同意海曲泊帕乙醇胺片进行临床试验的函，将于近期开展Ⅲ期临床试验。试验通俗题目：海曲泊帕治疗恶性肿瘤化疗所致血小板减少症的Ⅲ期临床研究试验。据悉，海曲泊帕乙醇胺片(商品名：恒曲)于2021年6月获得国家药品监督管理局批准用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/638846.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","relate_stocks":{"600276":"恒瑞医药","BK1576":"医药外包概念","BK1583":"高瓴概念","03347":"泰格医药","BK1141":"生命科学工具和服务"},"source_url":"http://www.zhitongcaijing.com/content/detail/638846.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2202204789","content_text":"智通财经APP讯，恒瑞医药(600276.SH)公告，近日，公司收到美国食品药品监督管理局(“美国FDA”)关于同意海曲泊帕乙醇胺片进行临床试验的函，将于近期开展Ⅲ期临床试验。试验通俗题目：海曲泊帕治疗恶性肿瘤化疗所致血小板减少症的Ⅲ期临床研究试验。据悉，海曲泊帕乙醇胺片(商品名：恒曲)于2021年6月获得国家药品监督管理局批准用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者的治疗，以及用于对免疫抑制治疗疗效不佳的重型再生障碍性贫血成人患者的治疗。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1305,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":23,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/697134127"}